JayMarshallFeingoldMD

PubMed

• 49 citations
  Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
  Mehdi Hamadani, Graham P. Collins, Paolo Caimi, Felipe Samaniego, Alexander I. Spira
  The Lancet. Haematology. 2021-06-01
• 210 citations
  Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
  Paolo Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani
  The Lancet. Oncology. 2021-06-01
• 108 citations
  Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
  Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Erin Reid
  Blood. 2021-05-13

Abstracts/Posters

• Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
  Jay Feingold, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018